EUVIMEDEUVIMED entdecken
Crossref

A multi-omics integration identifies ENY2 hypomethylation as a driver of immunosuppression and progression in breast cancer

Hong Wang, Yanmin Yu, Lingjia Meng, Wanli Zhou, Fei Chen, Zhe Li

Cellular Signalling · 2027-02 · 150 · 112925

DOI: 10.1016/j.cellsig.2026.112925 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cellular Signalling, 2027-02. Verfasst von Hong Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thyroid and Breast Surgery, Zhongshan Hospital, Fudan University, Shanghai, 200032, China. Die Arbeit nennt 40 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aberrant DNA methylation contributes to breast cancer (BC) progression and immune microenvironment dysregulation, but its underlying epigenetic-immune crosstalk remains poorly defined. This study constructed a methylation-driven prognostic signature in BC using the SIMPO algorithm and Cox regression with TCGA cohort data, validated externally in the GSE76427 cohort. Bioinformatic analyses including GSEA, CIBERSORT and TIMER were applied to characterize the immune microenvironment. Functional assays were performed in BC cell lines and mouse models with ENY2 knockdown, overexpression and 5-Aza-dC treatment, combined with scRNA-seq, ATAC-seq, Western blot, flow cytometry and other molecular techniques. The established prognostic model stratified patients into high- and low-risk groups, with high-risk patients exhibiting poorer survival and an immunosuppressive phenotype. ENY2 was identified as a critical oncogene driven by promoter hypomethylation alongside genomic copy number gain, whose expression was inversely correlated with promoter methylation. ENY2 promoted cancer cell malignant progression. Mechanistically, ENY2 hypomethylation enhanced chromatin accessibility, facilitated the recruitment of the transcription factor E2F1, and increased active histone marks, thereby driving ENY2 transcription. Furthermore, ENY2 remodeled the immunosuppressive microenvironment not only by activating the TNF-NF-κB/PD-L1 axis, but also by elevating immunosuppressive secretomes including MIF and MDK to impair CD8+T cell cytotoxicity. In vivo, ENY2 knockdown attenuated 5-Aza-dC-accelerated tumor growth and restored CD8+T cell infiltration. Our findings establish ENY2 as an important epigenetic-immune bridge and a therapeutic vulnerability in BC.

Schlagwörter

Stichwörter der Autor:innen

Breast cancerDNA methylationENY2Immune escapePrognosis

Autor:innen und Institutionen

  • Department of Thyroid and Breast Surgery, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
  • Department of Breast Surgery, Shanghai Second People's Hospital, Shanghai, 200011, China.
  • Department of Emergency Medicine, Putuo Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 200062, China.
  • Department of Breast Surgery, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China; Department of Thyroid and Breast Surgery, Sichuan Provincial Hospital for Women…
  • Department of Breast Surgery, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China. Electronic address: ruxianchen@shutcm.edu.cn.
  • Department of Breast Surgery, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China. Electronic address: lizhezsh@shutcm.edu.cn.

Zitieren

APA

Wang, H., Yu, Y., Meng, L., Zhou, W., Chen, F., & Li, Z. (2027). A multi-omics integration identifies ENY2 hypomethylation as a driver of immunosuppression and progression in breast cancer. Cellular Signalling, 150, 112925. https://doi.org/10.1016/j.cellsig.2026.112925

Vancouver

Wang H, Yu Y, Meng L, Zhou W, Chen F, Li Z. A multi-omics integration identifies ENY2 hypomethylation as a driver of immunosuppression and progression in breast cancer. Cellular Signalling. 2027;150:112925. doi:10.1016/j.cellsig.2026.112925

BibTeX
@article{Wang2027,
  author = {Wang, Hong and Yu, Yanmin and Meng, Lingjia and Zhou, Wanli and Chen, Fei and Li, Zhe},
  title = {A multi-omics integration identifies ENY2 hypomethylation as a driver of immunosuppression and progression in breast cancer},
  journal = {Cellular Signalling},
  year = {2027},
  volume = {150},
  pages = {112925},
  doi = {10.1016/j.cellsig.2026.112925}
}
Kostenlos starten →